Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Authors:
- 1 June 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 44 (6) , 1676-1681
Abstract
Background and Purpose—: To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin. Methods—: A Markov decision-analysis model was constructed using data from clinical trials to evaluate lifetime costs and quality-adjusted life-years of novel oral anticoagulants compared with warfarin. The modeled population was a hypothetical cohort of 70-year-old patients with nonvalvular atrial fibrillation, increased risk for stroke (CHADS 2 ≥1), renal creatinine clearance ≥50 mL/min, and no previous contraindications to anticoagulation. The willingness-to-pay threshold was $50 000/quality-adjusted life-years gained. Results—: In the base case, warfarin had the lowest cost of $77 813 (SD, $2223), followed by rivaroxaban 20 mg ($78 738±$1852), dabigatran 150 mg ($82 719±$1959), and apixaban 5 mg ($85 326±$1512). Apixaban 5 mg had the highest quality-adjusted life-years estimate at 8.47 (SD, 0.06), followed by dabigatran 150 mg (8.41±0.07), rivaroxaban 20 mg (8.26±0.06), and warfarin (7.97±0.04). In a Monte Carlo probabilistic sensitivity analysis, apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg, and warfarin were cost-effective in 45.1%, 40%, 14.9%, 0% of the simulations, respectively. Conclusions—: In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulantss was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg.Keywords
This publication has 34 references indexed in Scilit:
- Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial FibrillationThe American Journal of Cardiology, 2012
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic AttackStroke, 2012
- Heart Disease and Stroke Statistics—2012 UpdateCirculation, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary PreventionArchives of internal medicine (1960), 2011
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Preference-Based EQ-5D Index Scores for Chronic Conditions in the United StatesMedical Decision Making, 2006
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Prognosis after initial myocardial infarction: The Framingham studyThe American Journal of Cardiology, 1979